EcoDrugPlus

Solute Carrier Family 18 Member A2

Ensembl ID : ENSBTAG00000004739
Gene Symbol: SLC18A2
10 Enzyme and pathways 5 Cross references
234 Possible Orthologues:

Solute Carrier Family 22 Member 11

Ensembl ID : ENSBTAG00000018792
Gene Symbol: SLC22A11
5 Enzyme and pathways 5 Cross references
896 Possible Orthologues:

Solute Carrier Family 22 Member 12

Ensembl ID : ENSBTAG00000018762
Gene Symbol: SLC22A12
5 Enzyme and pathways 5 Cross references
487 Possible Orthologues:

Solute Carrier Family 22 Member 6

Ensembl ID : ENSBTAG00000013642
Gene Symbol: SLC22A6
5 Enzyme and pathways 4 Cross references
507 Possible Orthologues:

Solute Carrier Family 22 Member 8

Ensembl ID : ENSBTAG00000013644
Gene Symbol: SLC22A8
5 Enzyme and pathways 5 Cross references
316 Possible Orthologues:

Solute Carrier Family 29 Member 1

Ensembl ID : ENSBTAG00000015131
Gene Symbol: SLC29A1
7 Enzyme and pathways 5 Cross references
292 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSBTAG00000012851
Gene Symbol: SLC5A1
6 Enzyme and pathways 5 Cross references
262 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSBTAG00000010096
Gene Symbol: SLC5A2
3 Enzyme and pathways 5 Cross references
211 Possible Orthologues:

Solute Carrier Family 6 (Neurotransmitter Transporter, Glycine), Member 9-Like

Ensembl ID : ENSBTAG00000006043
Gene Symbol: LOC515755
4 Cross references
209 Possible Orthologues:

Solute Carrier Family 6 Member 1

Ensembl ID : ENSBTAG00000005857
Gene Symbol: SLC6A1
9 Enzyme and pathways 5 Cross references
293 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSBTAG00000003353
Gene Symbol: SLC6A2
4 Enzyme and pathways 5 Cross references
216 Possible Orthologues:

Solute Carrier Family 6 Member 3

Ensembl ID : ENSBTAG00000015843
Gene Symbol: SLC6A3
8 Enzyme and pathways 5 Cross references
178 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).